OsteoBites S1 Ep23: Brian Flesner, DVM, MS, DACVIM: "Adjuvant Chemotherapy for Canine Osteosarcoma ”
Play • 59 min

MIB Agents OsteoBites S1 Ep23: Brian Flesner, DVM, MS, DACVIM: "Adjuvant Chemotherapy for Canine Osteosarcoma”
Guest Information:
*Brian Flesner, DVM, MS, DACVIM
American College of Veterinary Internal Medicine (ACVIM)
Assistant Professor of Oncology
College of Veterinary Medicine at the University of Missouri
In addition to studying #osteosarcoma, Dr. Flesner’s research interests include chemotherapy mechanisms of action and toxicity, cancer-induced pain, and novel chemotherapeutic approaches to combat aggressive neoplasms. Extensively involved in the vibrant clinical trials service at the MU Veterinary Health Center. The trials service sees hundreds of patients annually; notably, 70 dogs with osteosarcoma were enrolled in osteosarcoma specific clinical trials in the past four years. Dr. Flesner is currently site principal-investigator for several ongoing osteosarcoma studies, including three near completion National Cancer Institute COTC nationwide trials.  
Panelists Information:
*Charlotte Murdoff, OsteoWarrior
*Casey Crossan, MIB Agents Development & Operations Chief
*Hosted By Ann Graham, OsteoWarrior & MIB Agents President
Next week on OsteoBites our guest will be Charles Keller, MD and Andy Wood of cc-TDI speaking on
"Legacy Autopsy Gifts: The After-LIfe Gift of Tissue".   
MIB Agents is a leading pediatric #osteosarcoma nonprofit dedicated to Making It Better for our community of patients, caregivers, doctors, and researchers with the goal of less toxic, more effective treatments and a cure for this aggressive bone cancer. More information at www.mibagents.org
Register: https://bit.ly/MIBobites

--- Support this podcast: https://anchor.fm/mibagents/support
More episodes
Clear search
Close search
Google apps
Main menu